

101 PCT/PTO 03 JUL 2002
10/088245

Attorney's Docket No. 9052-111

PATENT #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Antson et al. Examiner: To be assigned
Serial No.: 10/088,245 Group Art Unit: To be assigned
International Application No. PCT/GB00/03568
Filed: September 18, 2000 (I.A. Filing Date)
For: TARGET FOR ANTIVIRAL THERAPY

July 3, 2002

Box PCT
Commissioner for Patents
Washington, DC 20231
Attn: DO/EO/US


#3
Plunkett
11/27/02

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. The Commissioner is hereby authorized to charge any additional fee, which may be required, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,



Jarett K. Abramson
Registration No. 47,376



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 015809678 US

Date of Deposit: July 3, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT, Commissioner for Patents, Washington, DC 20231, Attn: DO/EO/US.



Susan E. Freedman

Date of Signature: July 3, 2002

Substitute form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/088,245
				Filing Date		
				First Named Inventor		Alfred Antson
				Group Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number		9052-111

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	WO	97/06246		Vertex Pharmaceuticals	02/20/1997		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T
	2	Gauthier et al., <i>Two DNA-Bound E2 Dimers are Required for Strong Transcriptional Activation and for Cooperation With Cellular Factors in Most Cells</i> , The New Biologist, Vol. 3, No. 5, May 1991, pp. 498-509					
	3	Harris et al., <i>Crystal Structure of the Human Papillomavirus Type 18 E2 Activation Domain</i> , Science, Vol. 284, June 4, 1999, pp. 1673-1677					
	4	Hegde et al., <i>Crystal Structure of the E2 DNA-Binding Domain From Human Papillomavirus Type 16: Implications for Its DNA Binding-Site Selection Mechanism</i> , J. Mol. Biol., Vol. 284, 1998, pp. 1479-1489					
	5	Hegde et al., <i>Subunit Rearrangement Accompanies Sequence-Specific DNA Binding by the Bovine Papillomavirus-1 E2 Protein</i> , J. Mol. Biol., Vol. 284, 1998, pp. 797-808					
	6	McBride et al., <i>E2 Polypeptides Encoded by Bovine Papillomavirus Type 1 Form Dimers Through the Common Carboxyl-Terminal Domain: Transactivation is Mediated by the Conserved Amino-Terminal Domain</i> , Proc. Natl. Acad. Sci. USA, Vol. 86, January 1989, pp. 510-514					
	7	Knight et al., <i>The Activation Domain of the Bovine Papillomavirus E2 Protein Mediates Association of DNA-Bound Dimers to Form DNA Loops</i> , Proc. Natl. Acad. Sci. USA, Vol. 88, April 1991, pp. 3204-3208					
	8	Cooper et al., <i>Identification of Single Amino Acids in the Human Papillomavirus 11 E2 Protein Critical for the Transactivation of the Replication Functions</i> , Virology, Vol. 241, 1998, pp. 312-322					
	9	Sakai et al., <i>Targeted Mutagenesis of the Human Papillomavirus Type 16 E2 Transactivation Domain Reveals Separable Transcriptional Activation and DNA Replication Functions</i> , Journal of Virology, March 1996, pp. 1602-1611					
	10	Yang et al., <i>Crystal Structure of Cyanovirin-N, a Potent HIV-Inactivating Protein, Shows Unexpected Domain Swapping</i> , J. Mol. Biol., Vol. 288, 1999, pp. 403-412					
	11	Ghose et al., <i>Determination of Pharmacophoric Geometry for Collagenase Inhibitors Using a Novel Computational Method and Its Verification Using Molecular Dynamics, NMR, and X-Ray Crystallography</i> , J. Am. Chem. Soc., Vol. 117, 1995, pp. 4671-4682					
	12	Wibley et al., <i>A Homology Model of the Three-Dimensional Structure of Human O⁶-Alkylguanine-DNA Alkyltransferase Based on the Crystal Structure of the C-Terminal Domain of the Ada Protein From Escherichia Coli</i> , Anti-Cancer Drug Design, Vol. 10, 1995, pp. 75-95					
	13	Antson et al., <i>Structure of the Intact Transactivation Domain of the Human Papillomavirus E2 Protein</i> , Nature, Vol. 403, February 17, 2000, pp. 805-809					
	14	Meyers et al., <i>Patent Protection for Protein Structures and Databases</i> , Nature Structural Biology, Structural Genomics Supplement, November 2000, pp. 950-952					
	15	Burns et al., <i>Expression, Crystallization and Preliminary X-Ray Analysis of the E2 Transactivation Domain From Papillomavirus Type 16</i> , Acta Cryst., Vol. D54, 1998, pp. 1471-1474					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.